Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055445 · ClinicalTrials.gov registry record · Phase 1
IdB 1016 Treatment for Hepatitis C Disease
A Phase 1 study of Hepatitis C, Chronic, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT00055445: Completed Phase 1 study of Hepatitis C, Chronic, sponsored by National Center for Complementary and Integrative Health (NCCIH).
NCT00055445 is a Phase 1 study of Hepatitis C, Chronic that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 45 participants, below the 374-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055445, a Phase 1 study of Hepatitis C, Chronic, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will measure the safety and tolerability of three different doses of IdB 1016 in patients with hepatitis C disease who have not responded to or are poor candidates for interferon-based therapies. NOTE: THE STUDY WILL ONLY RECRUIT STUDY PARTICIPANTS AT UNIVERSITY OF WASHINGTON MEDICAL CENTER IN SEATTLE
Conditions Studied
Interventions
- DRUG IdB 1016
Study Locations (1)
Washington
- University of Washington Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-04 |
| Phase | Phase 1 |
What the finished NCT00055445 record still lists
NCT00055445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 374-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 1 intervention - of which IdB 1016 is the first listed.
NCT00055445 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00055445 about?
NCT00055445 is a clinical study titled "IdB 1016 Treatment for Hepatitis C Disease". This study will measure the safety and tolerability of three different doses of IdB 1016 in patients with hepatitis C disease who have not responded to or are poor candidates for interferon-based therapies. NOTE: THE STUDY WILL ONLY RECRUIT STUDY PARTICIPANTS AT UNIVERSITY OF WASHINGTON MEDICAL CEN...
What is the current status of trial NCT00055445?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2003-11. Estimated completion is 2006-04.
What conditions does trial NCT00055445 study?
This clinical trial studies the following conditions: Hepatitis C, Chronic.
What interventions are being tested in trial NCT00055445?
The interventions under investigation include: IdB 1016 (DRUG).
Who is sponsoring clinical trial NCT00055445?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055445 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00055445's enrollment target sits among peer trials
45 25th of 26 higher than 2 of 26 other Hepatitis C, Chronic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C, Chronic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
COMPLETED · Phase 1
-
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
COMPLETED · Phase 1
-
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 1
-
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
RECRUITING · Phase 4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
ACTIVE NOT RECRUITING · Phase 4
-
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia